| Literature DB >> 34845873 |
Joung-Hee Byun1,2, Su Eun Park1,3, Minhae Seo1, Jeungmi Jang4, Mi Sun Hwang4, Ju Yeoun Song3,4, Chulhun L Chang5, Young A Kim1,6.
Abstract
BACKGROUND: Multidrug-resistant Acinetobacter baumannii (MDRAB) is widespread among intensive care units worldwide, posing a threat to patients and the health system. We describe the successful management of a MDRAB outbreak by implementing an infection-control strategy in a pediatric intensive care unit (PICU).Entities:
Keywords: Acinetobacter baumannii; Infection-control; Intensive Care Unit; Outbreak; Pediatric
Mesh:
Substances:
Year: 2021 PMID: 34845873 PMCID: PMC8629720 DOI: 10.3346/jkms.2021.36.e307
Source DB: PubMed Journal: J Korean Med Sci ISSN: 1011-8934 Impact factor: 2.153
Fig. 1Schematic map of the pediatric intensive care unit and the implementation of a comprehensive infection-control strategy. MDRAB-colonized patients were isolated in isolation rooms, or in the cohort zone if isolation rooms were unavailable. One entrance was closed. The asterisks represent the sites where MDRAB was detected.
MDRAB = multidrug-resistance A. baumannii.
Summary of the infection-control strategy for MDRAB outbreaks and comparisons with infection-control policies for MDRAB in our hospital
| Concepts | Implemented interventions | Details | Policies of our hospital |
|---|---|---|---|
| Cohort isolation | Cohort isolation of colonized patients | Mandatory | Recommended |
| Enforcement of hand hygiene | Regular education programs on hand hygiene | Including circulating staff | Not regular |
| Monitoring of hand hygiene performance | Daily for the first month; then three times per week | Twice a month | |
| Universal contact precautions | Wearing gloves and plastic gowns during contact in the patient zone | For all patients | For affected patients only |
| Environmental cleaning and disinfection | Extensive management using checklists | Under the supervision of the unit manager | None |
| Patient zone | Three times a day | Once a day | |
| Environment except the patient zone | Twice a day | Once a day | |
| Surveillance cultures | Initial and periodic cultures for all patients | Once a week | None |
| Environmental surveillance cultures | Once a week | None | |
| Assessment of bacterial colonization for staff | Including circulating staff | None | |
| Monitoring and feedback | Discussions on the performance of the infection-control strategy | Monthly | None |
MDRAB = multidrug-resistant A. baumannii.
In vitro activities of antimicrobial agents against A. baumannii isolated from the index case
| Antimicrobial agents | MIC | Activities |
|---|---|---|
| Ampicillin/sulbactam | 16 or ≥ 32 | I or R |
| Cefotaxime | ≥ 64 | R |
| Cefepime | ≥ 64 | R |
| Ceftazidime | ≥ 64 | R |
| Ciprofloxacin | ≥ 4 | R |
| Gentamicin | ≥ 16 | R |
| Imipenem | ≥ 16 | R |
| Meropenem | ≥ 16 | R |
| Minocycline | ≤ 1 | S |
| Piperacillin/tazobactam | ≥ 128 | R |
| Tigecycline | 4 | I |
| Trimethoprim/sulfamethoxazole | ≥ 160 or ≥ 320 | R |
| Colistin | ≤ 0.5 | S |
Four types of profiles were found depending on the minimal inhibitory concentration difference of ampicillin/sulbactam and trimethoprim/sulfamethoxazole.
MIC = minimal inhibitory concentration, I = intermediate, R = resistance, S = susceptible.
Fig. 2Monthly incidence of the MDRAB colonization and hand hygiene performance rate during MDRAB outbreak. A comprehensive infection-control strategy was implemented in January 2018. The overall incidence per 1,000 patient days decreased to 5.8 in period 2 from 7.8 in period 1. The last new colonization occurred in July 2018, and the last MDRAB colonization patient was discharged in August 2018. The MDRAB outbreak was declared terminated after the 6-month follow-up following period 2.
MDRAB = multidrug-resistance A. baumannii.
Clinical characteristics and outcomes of the patients in the MDRAB group and comparisons with the control group
| Variables | All (n = 427) | MDRAB (n = 29) | Control (n = 398) | ||
|---|---|---|---|---|---|
| Sex, male | 240 (56.2) | 21 (72.4) | 219 (55.0) | 0.082 | |
| Age, mon | 50.6 ± 68.7 | 14.8 ± 40.5 | 53.2 ± 69.6 | < 0.001 | |
| Underlying disease | 414 (97.0) | 29 (100) | 385 (96.7) | 0.395 | |
| Neurologic disease | 51 (11.9) | 4 (13.8) | 47 (11.8) | 0.208 | |
| Cardiovascular disease | 255 (59.7) | 22 (75.9) | 233 (58.5) | 0.029 | |
| Respiratory disease | 30 (7.0) | - | 30 (7.5) | 0.112 | |
| Renal disease | 22 (5.2) | - | 22 (5.5) | 0.204 | |
| Gastrointestinal disease | 14 (3.3) | 2 (6.9) | 12 (3.0) | 0.183 | |
| Hemato-oncologic disease | 30 (7.0) | 1 (3.4) | 29 (7.3) | 0.264 | |
| Metabolic disease | 12 (2.8) | - | 12 (3.0) | 0.425 | |
| Specific consideration | |||||
| Open heart surgery | 225 (52.7) | 22 (75.9) | 203 (51.0) | 0.012 | |
| Immunocompromised | 22 (5.2) | - | 22 (5.5) | 0.385 | |
| Mechanical ventilation | 350 (82.0) | 29 (100) | 321 (80.7) | 0.005 | |
| PRISM III score | 5.6 ± 5.5 | 7.8 ± 3.9 | 5.5 ± 5.6 | 0.025 | |
| MV days, day | 8.7 ± 19.4 | 38.0 ± 39.0 | 6.0 ± 13.8 | < 0.001 | |
| PICU stay, day | 9.1 ± 19.1 | 44.6 ± 41.9 | 6.5 ± 13.1 | < 0.001 | |
| Mortality | 34 (8.0) | 4a (13.8) | 30 (7.5) | 0.273 | |
Data are given as number (%) or mean ± standard deviation.
MDRAB = multidrug-resistance A. baumannii, PRISM III = Pediatric Risk of Mortality III, MV = mechanical ventilation, PICU = pediatric intensive care unit.
aMortality reported is unrelated to the MDRAB infection.